Recent biosimilar approvals granted by the U.S. Food and Drug Administration include interchangeable follow-on biologics targeting immunology, oncology, and ophthalmology, expanding patient access to more affordable treatments. These newly approved biological products match the safety, purity, and potency of reference reference drugs while helping lower overall healthcare system expenditures.